About: A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
Creator	Du, Lanying Jiang, Shibo Zhao, Guangyu Zheng, Bo-Jian Zhou, Yusen Ma, Cuiqing Wang, Lili Yu, Fei Li, Ye Li, Lin Poon, Vincent
source	Medline; PMC
abstract	BACKGROUND: Evidence points to the emergence of a novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), which causes a severe acute respiratory syndrome (SARS)-like disease. In response, the development of effective vaccines and therapeutics remains a clinical priority. To accomplish this, it is necessary to evaluate neutralizing antibodies and screen for MERS-CoV entry inhibitors. METHODS: In this study, we produced a pseudovirus bearing the full-length spike (S) protein of MERS-CoV in the Env-defective, luciferase-expressing HIV-1 backbone. We then established a pseudovirus-based inhibition assay to detect neutralizing antibodies and anti-MERS-CoV entry inhibitors. RESULTS: Our results demonstrated that the generated MERS-CoV pseudovirus allows for single-cycle infection of a variety of cells expressing dipeptidyl peptidase-4 (DPP4), the confirmed receptor for MERS-CoV. Consistent with the results from a live MERS-CoV-based inhibition assay, the antisera of mice vaccinated with a recombinant protein containing receptor-binding domain (RBD, residues 377–662) of MERS-CoV S fused with Fc of human IgG exhibited neutralizing antibody response against infection of MERS-CoV pseudovirus. Furthermore, one small molecule HIV entry inhibitor targeting gp41 (ADS-J1) and the 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA) could significantly inhibit MERS-CoV pseudovirus infection. CONCLUSION: Taken together, the established MERS-CoV inhibition assay is a safe and convenient pseudovirus-based alternative to BSL-3 live-virus restrictions and can be used to rapidly screen MERS-CoV entry inhibitors, as well as evaluate vaccine-induced neutralizing antibodies against the highly pathogenic MERS-CoV.
has issue date	2013-08-26(xsd:dateTime)
bibo:doi	10.1186/1743-422x-10-266
bibo:pmid	23978242
has license	cc-by
sha1sum (hex)	14c6dff031b3bcf8a7ea8486965b1dd888cf46a4
schema:url	https://doi.org/10.1186/1743-422x-10-266
resource representing a document's title	A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
has PubMed Central identifier	PMC3765664
has PubMed identifier	23978242
schema:publication	Virol J
resource representing a document's body	covid:14c6dff031b3bcf8a7ea8486965b1dd888cf46a4#body_text
is schema:about of	named entity 'SAFE' named entity 'fused' named entity 'MERS-CoV' named entity 'human' named entity 'highly' named entity 'Evidence' named entity 'MERS-CoV' named entity 'vaccines' named entity 'inhibition' named entity 'SCREEN' named entity 'EVIDENCE' named entity 'PRIORITY' named entity 'USED' named entity 'SAFE' named entity 'POINTS' named entity 'DEFECTIVE' named entity 'HUMAN SERUM ALBUMIN' named entity 'HSA' named entity 'VACCINATED' named entity 'SMALL MOLECULE' named entity 'PROTEIN ' named entity 'ASSAY' named entity 'GP41' named entity 'DIPEPTIDYL PEPTIDASE' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'BSL' named entity 'BINDING' named entity 'BACKGROUND' named entity 'HIGHLY' named entity 'VIRUS' named entity 'CAUSES' named entity 'RAPIDLY' named entity 'NEUTRALIZING ANTIBODY' named entity 'NOVEL' named entity 'STUDY' named entity 'CONCLUSION' named entity 'LENGTH' named entity 'RESPONSE' named entity 'ALLOWS' named entity 'ENV' named entity 'TO DETECT' named entity 'DISEASE' named entity 'FUSED WITH' named entity 'VACCINE' named entity 'EFFECTIVE' named entity 'TO DETECT' named entity 'ASSAY' named entity 'HUMAN CORONAVIRUS' named entity 'BEARING' named entity 'BASED' named entity 'INFECTION' named entity 'METHODS' named entity 'ANTISERA' named entity 'ESTABLISHED' named entity 'CONVENIENT' named entity '28S' named entity 'RESULTS' named entity 'ANTIBODY RESPONSE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'BASED' named entity 'ENTRY INHIBITORS' named entity 'CONVENIENT' named entity 'THERAPEUTICS' named entity 'EVALUATE' named entity 'INHIBITION' named entity 'VIRAL ENTRY' named entity 'PSEUDOVIRUS' named entity 'CYCLE' named entity 'INDUCED' named entity 'CONSISTENT WITH' named entity 'DOMAIN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software